• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dante Labs Announces Appointment of Healthcare Veteran and GRAIL SVP Mark Morgan to Board Of Directors to Support Genomic and Precision Medicine Scaling in the United States

    8/9/21 7:39:23 AM ET
    $AMGN
    $ANTM
    $ILMN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $AMGN alert in real time by email

    CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, announced today the appointment of Mark Morgan as a board member. Mark is the SVP of Market Access for GRAIL, which has developed a highly innovative multi-cancer, early detection blood test.

    "We are excited to welcome Mark Morgan to the Dante Labs Board," said Dante Labs CEO Andrea Riposati, "Mark is a rockstar in healthcare. His deep experience with health plans, coupled with market access expertise in both biopharma and diagnostics will be invaluable to Dante Labs as we continue to build on our global success and expansion in the United States."

    Mr. Morgan stated, "The opportunity to work with Dante Labs to accelerate adoption of whole genome sequencing in the US for patients with rare diseases, oncology, cardiovascular and other conditions is incredibly exciting."

    Mr. Morgan has deep experience with payors in the US market as well as market access in both the diagnostic and pharmaceutical spaces. His work at GRAIL and Amgen also focused heavily on the oncology space. He also serves as a board member for several additional healthcare focused organizations. Prior to GRAIL, Mr. Morgan held senior leadership roles in consumer markets and network management at Blue Shield of California. Prior to that, Mr. Morgan held leadership roles at Amgen (NASDAQ:AMGN), including Market Access and Value Based Partnerships. Mr. Morgan also served at the President of Anthem (NYSE:ANTM) in California, and held various additional leadership roles with the healthcare space in his nearly 30-year career. Mr. Morgan will join Illumina (NASDAQ:ILMN) Chief Operations Officer Bob Ragusa to Dante Labs Board of Directors.

    About Dante Labs

    Dante Labs is a global genomic data company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. Our assets include one of the largest private genome databases with research consent, a proprietary software platform designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Headquartered in Cambridge, United Kingdom, with a research laboratory in Wolverhampton, Dante Labs supported the UK Government's urgent requirement to scale-up a high-capacity, highly automated testing solution for Covid-19, including infected patients as well as those with antibodies. Dante Labs was able to deliver by leveraging existing technology that had been developed for whole genome sequencing.

    Contacts

    Giorgio Lodi

    [email protected]

    +39 0862 191 0671

    www.dantelabs.com 

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/93250a1b-93cb-40ac-80f2-b4981dfe61bc



    Primary Logo

    Get the next $AMGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMGN
    $ANTM
    $ILMN

    CompanyDatePrice TargetRatingAnalyst
    Amgen Inc.
    $AMGN
    9/3/2025Mkt Perform
    Raymond James
    Illumina Inc.
    $ILMN
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    Illumina Inc.
    $ILMN
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    Amgen Inc.
    $AMGN
    5/20/2025$288.00Neutral
    Guggenheim
    Amgen Inc.
    $AMGN
    4/22/2025$305.00Neutral
    Cantor Fitzgerald
    Illumina Inc.
    $ILMN
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    Illumina Inc.
    $ILMN
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    Illumina Inc.
    $ILMN
    2/10/2025$130.00 → $100.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $AMGN
    $ANTM
    $ILMN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for PAVBLU issued to AMGEN INC

    Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

    8/26/24 5:53:38 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    8/21/24 12:12:47 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $ANTM
    $ILMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Thaysen Jacob covered exercise/tax liability with 1,301 shares, decreasing direct ownership by 2% to 82,089 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    10/7/25 6:35:35 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Ullem Scott B. was granted 252 shares, increasing direct ownership by 3% to 8,389 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    10/2/25 4:06:14 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 287 shares, decreasing direct ownership by 0.85% to 33,546 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    9/9/25 7:01:47 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $AMGN
    $ANTM
    $ILMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James resumed coverage on Amgen

    Raymond James resumed coverage of Amgen with a rating of Mkt Perform

    9/3/25 8:26:50 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Illumina downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Illumina from Outperform to Neutral and set a new price target of $94.00

    8/12/25 7:55:50 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina downgraded by Scotiabank with a new price target

    Scotiabank downgraded Illumina from Sector Outperform to Sector Perform and set a new price target of $125.00

    7/11/25 8:11:04 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $AMGN
    $ANTM
    $ILMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:20:13 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Chief Executive Officer Thaysen Jacob bought $998,674 worth of shares (12,350 units at $80.86), increasing direct ownership by 17% to 83,390 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:18:28 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Thaysen Jacob bought $991,672 worth of shares (7,330 units at $135.29), increasing direct ownership by 97% to 14,861 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/26/24 8:57:29 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $AMGN
    $ANTM
    $ILMN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Amgen Inc.

    SCHEDULE 13G/A - AMGEN INC (0000318154) (Subject)

    9/8/25 11:06:01 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amgen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AMGEN INC (0000318154) (Filer)

    8/5/25 4:03:34 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Illumina Inc.

    10-Q - ILLUMINA, INC. (0001110803) (Filer)

    8/1/25 5:24:43 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $AMGN
    $ANTM
    $ILMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

    Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in adult and pediatric patients aged 12 years and older. TEZSPIRE is the first and only biologic approved for CRSwNP that targets thymic stromal lymphopoietin (TSLP). CRSwNP affects up to approximately 320 million people worldwide and is a complex epithelial-driven inflammatory condi

    10/17/25 4:00:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot

    Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map variants SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped read technology, evaluating its performance on regions of the genome that traditional short-read technologies historically have not resolved. GeneDx's early results illustrate the ability of constellation to rapidly identify hard-to-detect variants implicated in rare disease. GeneDx's Director

    10/15/25 9:15:00 AM ET
    $ILMN
    $WGS
    Medical Specialities
    Health Care
    Retail: Computer Software & Peripheral Equipment
    Technology

    Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights

    At ASHG, an early access customer from the London Health Sciences Center Research Institute will demonstrate the power of the 5-base genome for accelerating resolution of rare disease cases Proprietary 5-base chemistry and novel DRAGEN algorithms enable dual-omic inquiry, providing researchers with new tool for precision medicine breakthroughs SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the release of its novel 5-base solution, enabling researchers to pursue broader biological questions with accuracy and ease. The 5-base solution marks a major advancement in scalable multiomic analysis, enabling simultaneous detection of both genomic variants and DN

    10/15/25 9:15:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $AMGN
    $ANTM
    $ILMN
    Leadership Updates

    Live Leadership Updates

    View All

    Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases

    Brian McKernan joins as CEO to further advance Predicta's clinical impact, including its non-invasive diagnostic for Multiple Myeloma Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubscribed $23.4 million Series A led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute and Myeloma Solutions Fund. The capital will be used to expand Predicta's team and CLIA-approved lab infrastructure, and advance commercialization of the company's first

    10/1/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

    Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi) therapeutics, will utilize the AGD clinical genomic database to derive real-world insights and accelerate drug target discovery.

    9/18/25 9:15:00 AM ET
    $ALNY
    $ILMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    BioStem Technologies Appoints Brandon Poe as Chief Financial Officer

    POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. ("BioStem" or the "Company") (OTC:BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Brandon Poe as its Chief Financial Officer (CFO). Mr. Poe has served on BioStem's Board of Directors since 2022. Michael Fortunato, the Company's prior CFO, has assumed the role of Chief Accounting Officer. "I'm excited to welcome Brandon as CFO during this pivotal period of growth and innovation for BioStem," said Jason Matuszewski, Chairman and CEO. "Brandon brings proven financial leader

    8/14/25 4:01:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $AMGN
    $ANTM
    $ILMN
    Financials

    Live finance-specific insights

    View All

    FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

    Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in adult and pediatric patients aged 12 years and older. TEZSPIRE is the first and only biologic approved for CRSwNP that targets thymic stromal lymphopoietin (TSLP). CRSwNP affects up to approximately 320 million people worldwide and is a complex epithelial-driven inflammatory condi

    10/17/25 4:00:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025

    SAN DIEGO, Oct. 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the third quarter 2025 following the close of market on Thursday, October 30, 2025.  On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.  Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, October 30, 2025. Interested parties may access the live webcast via the Investor Info section of Ill

    10/14/25 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

    Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price  THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolucumab). This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial. In support of the Trump Administration's efforts to lower drug prices for Americans, Repatha will be available through AmgenNow at a monthly price of $239, nearly 60% lower than the current U.S. list price. The

    10/6/25 9:00:00 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $ANTM
    $ILMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care